CJC-1295DAC vs no-DAC, the Ipamorelin stack, and AU sourcing
A plain-language CJC-1295 reference for laboratory research: what the GHRH analog is, how the DAC and no-DAC forms differ, why it is studied with Ipamorelin, and the sourcing criteria that matter in Australia.
Get the CJC-1295 dosage + sourcing reference (DAC vs no-DAC, COA criteria). One email, no spam.
For research use only. Not for human consumption. Not approved as a therapeutic good in Australia. Not medical advice. In Australia these compounds are supplied for laboratory research only.
What is CJC-1295
A synthetic GHRH analog studied for growth-hormone release
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). In research settings it is studied for its ability to prompt the pituitary to release more growth hormone, which in turn raises circulating IGF-1.
Amino-acid backbone. CJC-1295 builds on the GHRH (1-29) fragment, the active core of the natural hormone.
Forms studied. With DAC (long-acting) and without DAC, often called mod GRF 1-29 (short-acting).
Approvals as a therapeutic good in Australia. CJC-1295 is a research chemical, not a registered medicine.
DAC vs no-DAC
The one distinction that changes everything: half-life
The whole CJC-1295 conversation turns on whether the molecule carries the Drug Affinity Complex. DAC binds it to albumin in the bloodstream, which is what stretches the half-life from minutes to days.
CJC-1295 with DAC
Long-acting form. Half-life reported in days.
- Extended half-life from the Drug Affinity Complex binding to albumin, reported in the range of several days per dose.
- Sustained elevation of GH and IGF-1 baseline rather than a single sharp spike.
- Fewer reconstitutions in a research protocol because the molecule persists longer between handlings.
CJC-1295 without DAC
Short-acting form, often labelled mod GRF 1-29.
- Short half-life reported around 30 minutes, clearing quickly after administration.
- Sharper, pulse-like GH release that more closely tracks the body's natural rhythm in study models.
- Frequently paired with a GHRP such as Ipamorelin to time the pulse, the basis of the classic research stack.
CJC-1295 and Ipamorelin: why they are studied together
CJC-1295 is a GHRH analog. Ipamorelin is a growth-hormone-releasing peptide (a GHRP). They act on two different receptors, so in research models the combination produces a larger, cleaner growth-hormone pulse than either compound alone.
- Two mechanisms: GHRH analog plus GHRP, hitting separate pathways
- Reported synergy: a stronger combined GH pulse than the sum of each alone
- Ipamorelin is studied as selective, with little reported effect on cortisol or prolactin
- The no-DAC form is the usual partner because its short pulse times well with Ipamorelin
Relative, not to scale. Illustrates the reported synergy direction, not a measured value.
Reported research reference
Dosage and handling, framed for the lab
The figures below are reported research reference ranges from the literature and supplier documentation, recorded for laboratory context only. They are not instructions for human use.
Reported dosage range
Research references commonly cite microgram-scale amounts per administration for the no-DAC form, with the DAC form dosed less often because of its longer half-life. Treat any number as a literature reference, never a human-use instruction.
Reconstitution
CJC-1295 ships as a lyophilised (freeze-dried) powder. In research protocols it is reconstituted with bacteriostatic water, added slowly down the vial wall, then swirled rather than shaken to protect the peptide.
Storage
Lyophilised vials are typically kept refrigerated and shielded from light; once reconstituted, the solution is refrigerated and used within a limited window. Cold-chain handling preserves potency for accurate research results.
Working with CJC-1295 in the lab
Handling notes for accurate, repeatable research
Peptide research lives or dies on handling. The same vial gives different numbers if the cold chain breaks or the reconstitution is sloppy. Four steps researchers track, recorded for reference only.
Verify the COA
Match the batch certificate of analysis to the vial before anything else: identity, purity, and mass.
Reconstitute gently
Run bacteriostatic water down the inside wall, then swirl. Do not inject the stream onto the powder or shake the vial.
Keep the cold chain
Refrigerate, keep out of light, and log the reconstitution date so the use window is tracked.
Record everything
Note concentration, volume drawn, and batch ID per run so results stay traceable and repeatable.
What the CJC-1295 research literature describes
Reported study attributes, recorded for laboratory context. Not human-use claims.
Buying CJC-1295 in Australia
Where to buy CJC-1295 in Australia: the criteria, not a vendor
This page does not sell or link to suppliers. It gives you the checklist to judge any source. In Australia these are research chemicals, supplied for laboratory research only, and quality between sources varies widely.
| Sourcing criterion | Source worth trusting | Source to skip |
|---|---|---|
| HPLC purity | 99% or higher, stated | No figure given |
| Certificate of analysis | Per batch, downloadable | None provided |
| Third-party testing | Independent lab, transparent | Claimed, never shown |
| Stock location | Australian local stock | Vague or offshore only |
| Labelling | Research use only, clear | Human-use or dosing claims |
| Batch traceability | Batch ID matches COA | No traceability |
CJC-1295 vs Ipamorelin
Same goal, different mechanism
A common research question is how CJC-1295 differs from Ipamorelin. They are not competitors. They are two halves of the stack, working on separate receptors.
GHRH analog
Mimics growth-hormone-releasing hormone.
- Acts on the GHRH receptor to raise the amount of GH the pituitary can release.
- Comes in two half-lives depending on the DAC, days or minutes.
GHRP (ghrelin mimetic)
A growth-hormone-releasing peptide.
- Acts on the ghrelin receptor to trigger the GH pulse itself, a different lever.
- Reported as selective, with little effect on cortisol or prolactin in studies.
Get the CJC-1295 reference
DAC vs no-DAC, the Ipamorelin stack, reported dosage ranges, and the COA sourcing checklist for Australia, in one email.
For research use only. One email, no spam.
FAQ
CJC-1295, answered
What is CJC-1295?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). In research settings it is studied for prompting the pituitary to release more growth hormone, which raises circulating IGF-1. It is a research chemical, not an approved medicine, supplied for laboratory research only.
CJC-1295 with or without DAC?
The difference is half-life. With DAC (Drug Affinity Complex) the molecule binds to albumin and stays active for several days, giving a sustained baseline. Without DAC, often called mod GRF 1-29, it clears in about 30 minutes and produces a sharper, pulse-like release that is usually paired with a GHRP.
What is the CJC-1295 dosage?
Reported research references commonly cite microgram-scale amounts per administration for the no-DAC form, with the DAC form dosed less often because of its longer half-life. These are literature reference ranges for laboratory research, not instructions for human use, and nothing here is dosing advice.
Why is CJC-1295 used with Ipamorelin?
CJC-1295 is a GHRH analog and Ipamorelin is a growth-hormone-releasing peptide (a GHRP). They act on two different receptors, so in research models the combination produces a larger, cleaner growth-hormone pulse than either compound alone. The short-acting no-DAC form is the usual partner.
CJC-1295 vs Ipamorelin: what is the difference?
They are not competitors but two halves of the same stack. CJC-1295 acts on the GHRH receptor to raise how much growth hormone can be released. Ipamorelin acts on the ghrelin receptor to trigger the pulse itself, and is reported as selective with little effect on cortisol or prolactin in studies.
Where can I buy CJC-1295 in Australia?
This page does not sell or link to suppliers. Judge any source by the criteria: HPLC purity of 99% or higher, a certificate of analysis per batch, transparent third-party testing, Australian local stock, clear research-use-only labelling, and a batch ID that matches the COA. Quality between sources varies widely.
Is CJC-1295 legal in Australia?
CJC-1295 is not an approved therapeutic good in Australia and is supplied for laboratory research only. It is not for human consumption and nothing on this page is medical advice. Researchers are responsible for compliance with all applicable laws and institutional rules.
What results does CJC-1295 research report?
The research literature describes elevated growth hormone and IGF-1 levels in study models, with the DAC form giving a sustained rise and the no-DAC form giving a sharper pulse. These are research-framed observations only, not promised human outcomes or therapeutic claims.